A CASE OF METHOTREXATE-INDUCED PHOTOSENTIVITY REACTION

Case report: Methotrexate is an essential drug effectively used in acute lymphoblastic leukemia. Doses above 500 mg/m2 are defined as high-dose methotrexate (HDMTX). Since HDMTX is known to cause serious morbidity, it is given with a standard rescue therapy to prevent toxicity. Besides myelosuppress...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Aslı Turgutoğlu Yılmaz, Dilek Gurlek Gokcebay, Ayca Koca Yozgat, H. Nese Yarali
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/b3c35cff9b3c4555a1f3c6c7ed1027da
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b3c35cff9b3c4555a1f3c6c7ed1027da
record_format	dspace
spelling	oai:doaj.org-article:b3c35cff9b3c4555a1f3c6c7ed1027da2021-11-10T04:38:27ZA CASE OF METHOTREXATE-INDUCED PHOTOSENTIVITY REACTION2531-137910.1016/j.htct.2021.10.1078https://doaj.org/article/b3c35cff9b3c4555a1f3c6c7ed1027da2021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2531137921012256https://doaj.org/toc/2531-1379Case report: Methotrexate is an essential drug effectively used in acute lymphoblastic leukemia. Doses above 500 mg/m2 are defined as high-dose methotrexate (HDMTX). Since HDMTX is known to cause serious morbidity, it is given with a standard rescue therapy to prevent toxicity. Besides myelosuppression and mucositis, other side effects of methotrexate are hepatotoxicity, erythema, desquamation, allergic reactions and neurotoxicity. Methotrexate is also associated with radiation recall and false photosensitivity. A 10-year-old girl with pre-B ALL underwent hematopoietic stem cell transplantation two times due to marrow and central nervous system (CNS) relapse. On the follow-up, 3 months later she had a bone marrow relapse. After remission obtained with high dose chemotherapy, maintenance treatment was given due to relapse/refractory disease. One year later she had isolated CNS relapse again and treated with intrathecal methotrexate, Ara-C and dexamethasone. The patient was started on relapse/refractory maintenance therapy, and 1 g/m2 methotrexate was given every 4 weeks. Immediately after intravenous methotrexate was given to the patient in the 13th week of her treatment, she complained of burning, pain and redness in the areas that had previously been desquamated due to sunburn. No additional treatment was given, except alkaline hydration and calcium folinate, when the findings were observed. The patient was started on antihistamine therapy. Methotrexate drug level reached 0.02 umol/L at the 54th hour, the i.v. hydration was stopped. The patient's red and itchy lesions healed within 2 days by benefiting from the antihistamine. She is being followed-up at our outpatient clinic weekly chemotherapy without any sign of relapse. This sunburn-like erythema after methotrexate administration might be associated with impaired mononuclear cell response in sun-exposed tissues. Our case stated that he went to the sea two weeks ago and that the bullae secondary to the sunburn that developed afterwards peeled off after they burst. In conclusion, patients with a history of recent generalized sunburn should have their methotrexate delayed to avoid this complication.Aslı Turgutoğlu YılmazDilek Gurlek GokcebayAyca Koca YozgatH. Nese YaraliElsevierarticleDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S58-S59 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Aslı Turgutoğlu Yılmaz Dilek Gurlek Gokcebay Ayca Koca Yozgat H. Nese Yarali A CASE OF METHOTREXATE-INDUCED PHOTOSENTIVITY REACTION
description	Case report: Methotrexate is an essential drug effectively used in acute lymphoblastic leukemia. Doses above 500 mg/m2 are defined as high-dose methotrexate (HDMTX). Since HDMTX is known to cause serious morbidity, it is given with a standard rescue therapy to prevent toxicity. Besides myelosuppression and mucositis, other side effects of methotrexate are hepatotoxicity, erythema, desquamation, allergic reactions and neurotoxicity. Methotrexate is also associated with radiation recall and false photosensitivity. A 10-year-old girl with pre-B ALL underwent hematopoietic stem cell transplantation two times due to marrow and central nervous system (CNS) relapse. On the follow-up, 3 months later she had a bone marrow relapse. After remission obtained with high dose chemotherapy, maintenance treatment was given due to relapse/refractory disease. One year later she had isolated CNS relapse again and treated with intrathecal methotrexate, Ara-C and dexamethasone. The patient was started on relapse/refractory maintenance therapy, and 1 g/m2 methotrexate was given every 4 weeks. Immediately after intravenous methotrexate was given to the patient in the 13th week of her treatment, she complained of burning, pain and redness in the areas that had previously been desquamated due to sunburn. No additional treatment was given, except alkaline hydration and calcium folinate, when the findings were observed. The patient was started on antihistamine therapy. Methotrexate drug level reached 0.02 umol/L at the 54th hour, the i.v. hydration was stopped. The patient's red and itchy lesions healed within 2 days by benefiting from the antihistamine. She is being followed-up at our outpatient clinic weekly chemotherapy without any sign of relapse. This sunburn-like erythema after methotrexate administration might be associated with impaired mononuclear cell response in sun-exposed tissues. Our case stated that he went to the sea two weeks ago and that the bullae secondary to the sunburn that developed afterwards peeled off after they burst. In conclusion, patients with a history of recent generalized sunburn should have their methotrexate delayed to avoid this complication.
format	article
author	Aslı Turgutoğlu Yılmaz Dilek Gurlek Gokcebay Ayca Koca Yozgat H. Nese Yarali
author_facet	Aslı Turgutoğlu Yılmaz Dilek Gurlek Gokcebay Ayca Koca Yozgat H. Nese Yarali
author_sort	Aslı Turgutoğlu Yılmaz
title	A CASE OF METHOTREXATE-INDUCED PHOTOSENTIVITY REACTION
title_short	A CASE OF METHOTREXATE-INDUCED PHOTOSENTIVITY REACTION
title_full	A CASE OF METHOTREXATE-INDUCED PHOTOSENTIVITY REACTION
title_fullStr	A CASE OF METHOTREXATE-INDUCED PHOTOSENTIVITY REACTION
title_full_unstemmed	A CASE OF METHOTREXATE-INDUCED PHOTOSENTIVITY REACTION
title_sort	case of methotrexate-induced photosentivity reaction
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/b3c35cff9b3c4555a1f3c6c7ed1027da
work_keys_str_mv	AT aslıturgutogluyılmaz acaseofmethotrexateinducedphotosentivityreaction AT dilekgurlekgokcebay acaseofmethotrexateinducedphotosentivityreaction AT aycakocayozgat acaseofmethotrexateinducedphotosentivityreaction AT hneseyarali acaseofmethotrexateinducedphotosentivityreaction AT aslıturgutogluyılmaz caseofmethotrexateinducedphotosentivityreaction AT dilekgurlekgokcebay caseofmethotrexateinducedphotosentivityreaction AT aycakocayozgat caseofmethotrexateinducedphotosentivityreaction AT hneseyarali caseofmethotrexateinducedphotosentivityreaction
_version_	1718440589997899776

A CASE OF METHOTREXATE-INDUCED PHOTOSENTIVITY REACTION

Ejemplares similares